Patents by Inventor Moreno DI MARCO
Moreno DI MARCO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346837Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: March 2, 2023Publication date: November 2, 2023Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Patent number: 11559550Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 17, 2022Date of Patent: January 24, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Patent number: 11560405Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: July 8, 2022Date of Patent: January 24, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Patent number: 11542303Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 25, 2021Date of Patent: January 3, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Publication number: 20220362302Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 17, 2022Publication date: November 17, 2022Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Publication number: 20220356208Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: July 8, 2022Publication date: November 10, 2022Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Publication number: 20220332760Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 24, 2022Publication date: October 20, 2022Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Patent number: 11427614Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 10, 2018Date of Patent: August 30, 2022Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Publication number: 20220118016Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 23, 2021Publication date: April 21, 2022Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Publication number: 20210322478Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 25, 2021Publication date: October 21, 2021Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Patent number: 11135246Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 21, 2020Date of Patent: October 5, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Patent number: 11103534Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 30, 2020Date of Patent: August 31, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Publication number: 20210213065Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: January 21, 2021Publication date: July 15, 2021Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Publication number: 20210161962Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: January 21, 2021Publication date: June 3, 2021Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Patent number: 11020432Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 18, 2020Date of Patent: June 1, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Patent number: 11007223Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 28, 2020Date of Patent: May 18, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Patent number: 10993963Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 18, 2020Date of Patent: May 4, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Patent number: 10899819Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 10, 2018Date of Patent: January 26, 2021Assignee: Immatics Biotechnologies GmbHInventors: Juliane Sarah Walz, Daniel Kowalewski, Markus Löffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
-
Publication number: 20200339656Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 29, 2020Publication date: October 29, 2020Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
-
Publication number: 20200339657Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 30, 2020Publication date: October 29, 2020Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN